Difference between revisions of "Classical Hodgkin lymphoma, pediatric - historical"
Warner-admin (talk | contribs) m (Text replacement - "[[Hodgkin_lymphoma_" to "[[Classical_Hodgkin_lymphoma_") |
m |
||
(8 intermediate revisions by 2 users not shown) | |||
Line 3: | Line 3: | ||
[[#top|Back to Top]] | [[#top|Back to Top]] | ||
</div> | </div> | ||
− | The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only | + | The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the [[Classical_Hodgkin_lymphoma, pediatric|main pediatric Hodgkin lymphoma page]] for current regimens. |
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
Line 13: | Line 13: | ||
==ABVE {{#subobject:c24h71|Regimen=1}}== | ==ABVE {{#subobject:c24h71|Regimen=1}}== | ||
ABVE: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''incristine, '''<u>E</u>'''toposide | ABVE: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''incristine, '''<u>E</u>'''toposide | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen {{#subobject:7fa7ya|Variant=1}}=== | ===Regimen {{#subobject:7fa7ya|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
Line 42: | Line 42: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''POG P9426:''' Tebbi CK, Mendenhall NP, London WB, Williams JL, Hutchison RE, Fitzgerald TJ, de Alarcón PA, Schwartz C, Chauvenet A. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Dec 15;59(7):1259-65. Epub 2012 Aug 21. [https://doi.org/10.1002/pbc.24279 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3468662/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22911615/ PubMed] [https://clinicaltrials.gov/ | + | #'''POG P9426:''' Tebbi CK, Mendenhall NP, London WB, Williams JL, Hutchison RE, Fitzgerald TJ, de Alarcón PA, Schwartz C, Chauvenet A. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Dec 15;59(7):1259-65. Epub 2012 Aug 21. [https://doi.org/10.1002/pbc.24279 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3468662/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22911615/ PubMed] [https://clinicaltrials.gov/study/NCT00002827 NCT00002827] |
==ABVE-PC {{#subobject:c24d93|Regimen=1}}== | ==ABVE-PC {{#subobject:c24d93|Regimen=1}}== | ||
ABVE-PC: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''incristine, '''<u>E</u>'''toposide, '''<u>P</u>'''rednisone, '''<u>C</u>'''yclophosphamide | ABVE-PC: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''incristine, '''<u>E</u>'''toposide, '''<u>P</u>'''rednisone, '''<u>C</u>'''yclophosphamide | ||
</div></div><br> | </div></div><br> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen variant #2, 3 cycles with response adaptation {{#subobject:14cd95|Variant=1}}=== | ===Regimen variant #2, 3 cycles with response adaptation {{#subobject:14cd95|Variant=1}}=== | ||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
Line 74: | Line 74: | ||
<div class="toccolours" style="background-color:#cbd5e7"> | <div class="toccolours" style="background-color:#cbd5e7"> | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
− | *POG P9425, rapid early responders: [[#Radiation_therapy_2|IFRT]] consolidation x | + | *POG P9425, rapid early responders: [[#Radiation_therapy_2|IFRT]] consolidation x 2100 cGy |
− | *POG P9425, slow early responders: [[#ABVE-PC|ABVE-PC]] x 2 (5 cycles total), then [[#Radiation_therapy_2|IFRT]] consolidation x | + | *POG P9425, slow early responders: [[#ABVE-PC|ABVE-PC]] continuation x 2 (5 cycles total), then [[#Radiation_therapy_2|IFRT]] consolidation x 2100 cGy |
</div></div><br> | </div></div><br> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen variant #4, 5 cycles {{#subobject:7e95ea|Variant=1}}=== | ===Regimen variant #4, 5 cycles {{#subobject:7e95ea|Variant=1}}=== | ||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
Line 90: | Line 90: | ||
<div class="toccolours" style="background-color:#cbd5e8"> | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
− | *[[#ABVE-PC|ABVE-PC]] x 3, with slow early response | + | *Induction [[#ABVE-PC|ABVE-PC]] x 3, with slow early response |
</div> | </div> | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
Line 108: | Line 108: | ||
<div class="toccolours" style="background-color:#cbd5e7"> | <div class="toccolours" style="background-color:#cbd5e7"> | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
− | *[[#Radiation_therapy_2|IFRT]] consolidation x | + | *[[#Radiation_therapy_2|IFRT]] consolidation x 2100 cGy |
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''POG P9425:''' Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R, Lipshultz SE, Turner CS, deAlarcon PA, Chauvenet A. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009 Sep 3;114(10):2051-9. Epub 2009 Jul 7. Erratum: in Blood 2016 128:605 [ | + | #'''POG P9425:''' Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R, Lipshultz SE, Turner CS, deAlarcon PA, Chauvenet A. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009 Sep 3;114(10):2051-9. Epub 2009 Jul 7. Erratum: in Blood 2016 128:605 [https://doi.org/10.1182/blood-2008-10-184143 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744567/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19584400/ PubMed] [https://clinicaltrials.gov/study/NCT00005578 NCT00005578] |
==MOPP {{#subobject:bcde0|Regimen=1}}== | ==MOPP {{#subobject:bcde0|Regimen=1}}== | ||
MOPP: '''<u>M</u>'''echlorethamine, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | MOPP: '''<u>M</u>'''echlorethamine, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | ||
</div></div><br> | </div></div><br> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen variant #3, uncapped vincristine {{#subobject:ff7478|Variant=1}}=== | ===Regimen variant #3, uncapped vincristine {{#subobject:ff7478|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
Line 122: | Line 122: | ||
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1182/blood.V42.2.163.163 Young et al. 1973a] |
|1964-NR | |1964-NR | ||
| style="background-color:#91cf61" |Non-randomized (RT) | | style="background-color:#91cf61" |Non-randomized (RT) | ||
Line 141: | Line 141: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #Young RC, DeVita VT, Johnson RE. Hodgkin's disease in childhood. Blood. 1973 Aug;42(2):163-74. [ | + | #Young RC, DeVita VT, Johnson RE. Hodgkin's disease in childhood. Blood. 1973 Aug;42(2):163-74. [https://doi.org/10.1182/blood.V42.2.163.163 link to original article] [https://pubmed.ncbi.nlm.nih.gov/4793108/ PubMed] |
#Kolygin BA. Combination chemotherapy of Hodgkin's disease in children. Cancer. 1976 Oct;38(4):1494-7. [https://doi.org/10.1002/1097-0142(197610)38:4%3C1494::AID-CNCR2820380408%3E3.0.CO;2-E link to original article] [https://pubmed.ncbi.nlm.nih.gov/991072/ PubMed] | #Kolygin BA. Combination chemotherapy of Hodgkin's disease in children. Cancer. 1976 Oct;38(4):1494-7. [https://doi.org/10.1002/1097-0142(197610)38:4%3C1494::AID-CNCR2820380408%3E3.0.CO;2-E link to original article] [https://pubmed.ncbi.nlm.nih.gov/991072/ PubMed] | ||
==OPPA {{#subobject:6418c0|Regimen=1}}== | ==OPPA {{#subobject:6418c0|Regimen=1}}== | ||
OPPA: '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone, '''<u>A</u>'''driamycin (Doxorubicin) | OPPA: '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone, '''<u>A</u>'''driamycin (Doxorubicin) | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen {{#subobject:e17569|Variant=1}}=== | ===Regimen {{#subobject:e17569|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
Line 170: | Line 170: | ||
<div class="toccolours" style="background-color:#cbd5e7"> | <div class="toccolours" style="background-color:#cbd5e7"> | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
− | *GPOH-HD-2002, treatment group 2: [[#C-MOPP|COPP]] x 2 | + | *GPOH-HD-2002, treatment group 2: [[#C-MOPP|COPP]] consolidation x 2 |
− | *GPOH-HD-2002, treatment group 3: [[#C-MOPP|COPP]] x 4 | + | *GPOH-HD-2002, treatment group 3: [[#C-MOPP|COPP]] consolidation x 4 |
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''GPOH-HD-2002:''' Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. [https://doi.org/10.1200/jco.2009.26.9381 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/20625128/ PubMed] [https://clinicaltrials.gov/ | + | #'''GPOH-HD-2002:''' Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. [https://doi.org/10.1200/jco.2009.26.9381 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/20625128/ PubMed] [https://clinicaltrials.gov/study/NCT00416832 NCT00416832] |
==VAMP (Methotrexate) {{#subobject:4d666a|Regimen=1}}== | ==VAMP (Methotrexate) {{#subobject:4d666a|Regimen=1}}== | ||
VAMP: '''<u>V</u>'''inblastine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>M</u>'''ethrotrexate, '''<u>P</u>'''rednisone | VAMP: '''<u>V</u>'''inblastine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>M</u>'''ethrotrexate, '''<u>P</u>'''rednisone | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen {{#subobject:6f694d|Variant=1}}=== | ===Regimen {{#subobject:6f694d|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
Line 193: | Line 193: | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Vinblastine (Velban)]] | + | *[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15 |
− | *[[Doxorubicin (Adriamycin)]] | + | *[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15 |
− | *[[Methotrexate (MTX)]] | + | *[[Methotrexate (MTX)]] 20 mg/m<sup>2</sup> IV once per day on days 1 & 15 |
====Glucocorticoid therapy==== | ====Glucocorticoid therapy==== | ||
− | *[[Prednisone (Sterapred)]] | + | *[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14 |
− | '''4 cycles''' | + | '''28-day cycle for 4 cycles''' |
</div> | </div> | ||
<div class="toccolours" style="background-color:#cbd5e7"> | <div class="toccolours" style="background-color:#cbd5e7"> | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
− | *HOD99, early responders: [[Classical_Hodgkin_lymphoma_-_null_regimens#Observation|Observation]] versus [[#Radiation_therapy_2|RT]] | + | *HOD99, early responders: [[Classical_Hodgkin_lymphoma_-_null_regimens#Observation|Observation]] versus [[#Radiation_therapy_2|RT]] consolidation |
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''HOD99:''' Metzger ML, Weinstein HJ, Hudson MM, Billett AL, Larsen EC, Friedmann A, Howard SC, Donaldson SS, Krasin MJ, Kun LE, Marcus KJ, Yock TI, Tarbell N, Billups CA, Wu J, Link MP. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA. 2012 Jun 27;307(24):2609-16. [https:// | + | #'''HOD99:''' Metzger ML, Weinstein HJ, Hudson MM, Billett AL, Larsen EC, Friedmann A, Howard SC, Donaldson SS, Krasin MJ, Kun LE, Marcus KJ, Yock TI, Tarbell N, Billups CA, Wu J, Link MP. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA. 2012 Jun 27;307(24):2609-16. [https://doi.org/10.1001/jama.2012.5847 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526806/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22735430/ PubMed] |
=Consolidation after upfront therapy= | =Consolidation after upfront therapy= | ||
Line 211: | Line 211: | ||
C-MOPP: '''<u>C</u>'''yclophospha'''<u>M</u>'''ide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | C-MOPP: '''<u>C</u>'''yclophospha'''<u>M</u>'''ide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | ||
<br>COPP: '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | <br>COPP: '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen variant #1, 2 cycles {{#subobject:cfcc4b|Variant=1}}=== | ===Regimen variant #1, 2 cycles {{#subobject:cfcc4b|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
Line 225: | Line 225: | ||
<div class="toccolours" style="background-color:#cbd5e8"> | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
− | *[[#OPPA|OPPA]] x 2 | + | *Induction [[#OPPA|OPPA]] x 2 |
</div> | </div> | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
Line 236: | Line 236: | ||
'''28-day cycle for 2 cycles''' | '''28-day cycle for 2 cycles''' | ||
</div></div><br> | </div></div><br> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen variant #2, 4 cycles {{#subobject:228db9|Variant=1}}=== | ===Regimen variant #2, 4 cycles {{#subobject:228db9|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
Line 250: | Line 250: | ||
<div class="toccolours" style="background-color:#cbd5e8"> | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
− | *[[#OPPA|OPPA]] x 2 | + | *Induction [[#OPPA|OPPA]] x 2 |
</div> | </div> | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
Line 262: | Line 262: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''GPOH-HD-2002:''' Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. [https://doi.org/10.1200/jco.2009.26.9381 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/20625128/ PubMed] [https://clinicaltrials.gov/ | + | #'''GPOH-HD-2002:''' Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. [https://doi.org/10.1200/jco.2009.26.9381 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/20625128/ PubMed] [https://clinicaltrials.gov/study/NCT00416832 NCT00416832] |
==COPDAC {{#subobject:195ad7|Regimen=1}}== | ==COPDAC {{#subobject:195ad7|Regimen=1}}== | ||
COPDAC: '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone, '''<u>DAC</u>'''arbazine | COPDAC: '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone, '''<u>DAC</u>'''arbazine | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen variant #1, 2 cycles {{#subobject:e9d06d|Variant=1}}=== | ===Regimen variant #1, 2 cycles {{#subobject:e9d06d|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
Line 279: | Line 279: | ||
<div class="toccolours" style="background-color:#cbd5e8"> | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
− | *[[#OEPA|OEPA]] x 2 | + | *Induction [[#OEPA|OEPA]] x 2 |
</div> | </div> | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
Line 290: | Line 290: | ||
'''28-day cycle for 2 cycles''' | '''28-day cycle for 2 cycles''' | ||
</div></div><br> | </div></div><br> | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen variant #2, 4 cycles {{#subobject:515d30|Variant=1}}=== | ===Regimen variant #2, 4 cycles {{#subobject:515d30|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
Line 304: | Line 304: | ||
<div class="toccolours" style="background-color:#cbd5e8"> | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
− | *[[#OEPA|OEPA]] x 2 | + | *Induction [[#OEPA|OEPA]] x 2 |
</div> | </div> | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
Line 316: | Line 316: | ||
</div></div> | </div></div> | ||
===References === | ===References === | ||
− | #'''GPOH-HD-2002:''' Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. [https://doi.org/10.1200/jco.2009.26.9381 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/20625128/ PubMed] [https://clinicaltrials.gov/ | + | #'''GPOH-HD-2002:''' Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. [https://doi.org/10.1200/jco.2009.26.9381 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/20625128/ PubMed] [https://clinicaltrials.gov/study/NCT00416832 NCT00416832] |
[[Category:Classical Hodgkin lymphoma regimens]] | [[Category:Classical Hodgkin lymphoma regimens]] |
Latest revision as of 00:43, 27 June 2024
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main pediatric Hodgkin lymphoma page for current regimens.
7 regimens on this page
10 variants on this page
|
Untreated
ABVE
ABVE: Adriamycin (Doxorubicin), Bleomycin, Vincristine, Etoposide
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Tebbi et al. 2012 (POG P9426) | 1996-2001 | Non-randomized (see note) |
Note: this trial had a randomization to receive or not receive dexrazoxane. Labeled here as non-randomized because this drug does not have antineoplastic properties.
Chemotherapy
- Doxorubicin (Adriamycin) 25 mg/m2 IV once per day on days 1 & 15
- Bleomycin (Blenoxane) 10 units/m2 IV once per day on days 1 & 15
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 1 & 15
- Etoposide (Vepesid) 100 mg/m2 IV once per day on days 1 to 5
Supportive therapy
- Filgrastim (Neupogen) 5 mcg/kg SC once per day on days 6 to 14, then once per day on days 16 until ANC greater than 1000/μL
28-day cycle for 2 cycles
References
- POG P9426: Tebbi CK, Mendenhall NP, London WB, Williams JL, Hutchison RE, Fitzgerald TJ, de Alarcón PA, Schwartz C, Chauvenet A. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Dec 15;59(7):1259-65. Epub 2012 Aug 21. link to original article link to PMC article contains dosing details in manuscript PubMed NCT00002827
ABVE-PC
ABVE-PC: Adriamycin (Doxorubicin), Bleomycin, Vincristine, Etoposide, Prednisone, Cyclophosphamide
Regimen variant #2, 3 cycles with response adaptation
Study | Evidence |
---|---|
Schwartz et al. 2009 (POG P9425) | Phase 2 |
Note: This regimen is intended for pediatric patients, younger than 22 years old. Note that first day of chemotherapy is day 0. Bleomycin and prednisone dosing is post-amendment.
Chemotherapy
- Doxorubicin (Adriamycin) 30 mg/m2 IV once per day on days 0 & 1
- Bleomycin (Blenoxane) 10 units/m2 IV or SC once per day on days 0 & 7
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2.8 mg) IV once per day on days 0 & 7
- Etoposide (Vepesid) 75 mg/m2 IV once per day on days 0 to 4
- Cyclophosphamide (Cytoxan) 800 mg/m2 IV once on day 0
Glucocorticoid therapy
- Prednisone (Sterapred) 40 mg/m2 PO once per day on days 0 to 7
Supportive therapy
- Dexrazoxane (Zinecard) 300 mg/m2 IV once per day on days 0, 1, 7 (this was a randomization)
- Filgrastim (Neupogen) 5 mcg/kg IV or SC once per day from day 5 until neutrophil recovery (held on day 7)
21-day cycle for 3 cycles
Regimen variant #4, 5 cycles
Study | Evidence |
---|---|
Schwartz et al. 2009 (POG P9425) | Phase 2 |
Note: This regimen is intended for pediatric patients, younger than 22 years old, who are slow early responders. Note that first day of chemotherapy is day 0. Bleomycin and prednisone dosing is post-amendment.
Preceding treatment
- Induction ABVE-PC x 3, with slow early response
Chemotherapy
- Doxorubicin (Adriamycin) 30 mg/m2 IV once per day on days 0 & 1
- Bleomycin (Blenoxane) 10 units/m2 IV or SC once per day on days 0 & 7
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2.8 mg) IV once per day on days 0 & 7
- Etoposide (Vepesid) 75 mg/m2 IV once per day on days 0 to 4
- Cyclophosphamide (Cytoxan) 800 mg/m2 IV once on day 0
Glucocorticoid therapy
- Prednisone (Sterapred) 40 mg/m2 PO once per day on days 0 to 7
Supportive therapy
- Dexrazoxane (Zinecard) 300 mg/m2 IV once per day on days 0, 1, 7 (this was a randomization)
- Filgrastim (Neupogen) 5 mcg/kg IV or SC once per day from day 5 until neutrophil recovery (held on day 7)
21-day cycle for 5 cycles, including the first 3 cycles
Subsequent treatment
- IFRT consolidation x 2100 cGy
References
- POG P9425: Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R, Lipshultz SE, Turner CS, deAlarcon PA, Chauvenet A. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009 Sep 3;114(10):2051-9. Epub 2009 Jul 7. Erratum: in Blood 2016 128:605 link to original article contains dosing details in manuscript link to PMC article PubMed NCT00005578
MOPP
MOPP: Mechlorethamine, Oncovin (Vincristine), Procarbazine, Prednisone
Regimen variant #3, uncapped vincristine
Study | Dates of enrollment | Evidence |
---|---|---|
Young et al. 1973a | 1964-NR | Non-randomized (RT) |
Kolygin 1976 | 1970-1975 | Non-randomized (RT) |
Chemotherapy
- Mechlorethamine (Mustargen) 6 mg/m2 IV once per day on days 1 & 8
- Vincristine (Oncovin) 1.4 mg/m2 IV once per day on days 1 & 8
- Procarbazine (Matulane) 100 mg/m2 PO once per day on days 1 to 14
Glucocorticoid therapy
- Prednisone (Sterapred) 40 mg/m2 PO once per day on days 1 to 14
28-day cycle for 6 to 8 cycles
References
- Young RC, DeVita VT, Johnson RE. Hodgkin's disease in childhood. Blood. 1973 Aug;42(2):163-74. link to original article PubMed
- Kolygin BA. Combination chemotherapy of Hodgkin's disease in children. Cancer. 1976 Oct;38(4):1494-7. link to original article PubMed
OPPA
OPPA: Oncovin (Vincristine), Procarbazine, Prednisone, Adriamycin (Doxorubicin)
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Mauz-Körholz et al. 2010 (GPOH-HD-2002) | 2002-2005 | Phase 2 |
Note: This regimen is meant for girls. Patients with early-stage disease only received the OPPA portion, see text for details.
Chemotherapy
- Vincristine (Oncovin) 1.5 mg/m2 IV once per day on days 1, 8, 15
- Procarbazine (Matulane) 100 mg/m2 PO once per day on days 1 to 15
- Doxorubicin (Adriamycin) 40 mg/m2 IV once per day on days 1 & 15
Glucocorticoid therapy
- Prednisone (Sterapred) 60 mg/m2 PO once per day on days 1 to 15
28-day cycle for 2 cycles
References
- GPOH-HD-2002: Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. link to original article contains dosing details in manuscript PubMed NCT00416832
VAMP (Methotrexate)
VAMP: Vinblastine, Adriamycin (Doxorubicin), Methrotrexate, Prednisone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Metzger et al. 2012 (HOD99) | 2000-03-03 to 2008-12-09 | Phase 2 |
Note: This is to be distinguished from the VAMP protocols used in AML and multiple myeloma.
Chemotherapy
- Vinblastine (Velban) 6 mg/m2 IV once per day on days 1 & 15
- Doxorubicin (Adriamycin) 25 mg/m2 IV once per day on days 1 & 15
- Methotrexate (MTX) 20 mg/m2 IV once per day on days 1 & 15
Glucocorticoid therapy
- Prednisone (Sterapred) 40 mg/m2 PO once per day on days 1 to 14
28-day cycle for 4 cycles
Subsequent treatment
- HOD99, early responders: Observation versus RT consolidation
References
- HOD99: Metzger ML, Weinstein HJ, Hudson MM, Billett AL, Larsen EC, Friedmann A, Howard SC, Donaldson SS, Krasin MJ, Kun LE, Marcus KJ, Yock TI, Tarbell N, Billups CA, Wu J, Link MP. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA. 2012 Jun 27;307(24):2609-16. link to original article link to PMC article contains dosing details in manuscript PubMed
Consolidation after upfront therapy
C-MOPP
C-MOPP: CyclophosphaMide, Oncovin (Vincristine), Procarbazine, Prednisone
COPP: Cyclophosphamide, Oncovin (Vincristine), Procarbazine, Prednisone
Regimen variant #1, 2 cycles
Study | Dates of enrollment | Evidence |
---|---|---|
Mauz-Körholz et al. 2010 (GPOH-HD-2002) | 2002-2005 | Phase 2 |
Preceding treatment
- Induction OPPA x 2
Chemotherapy
- Cyclophosphamide (Cytoxan) 500 mg/m2 IV once per day on days 1 & 8
- Vincristine (Oncovin) 1.5 mg/m2 IV once per day on days 1 & 8
- Procarbazine (Matulane) 100 mg/m2 PO once per day on days 1 to 15
Glucocorticoid therapy
- Prednisone (Sterapred) 40 mg/m2 PO once per day on days 1 to 15
28-day cycle for 2 cycles
Regimen variant #2, 4 cycles
Study | Dates of enrollment | Evidence |
---|---|---|
Mauz-Körholz et al. 2010 (GPOH-HD-2002) | 2002-2005 | Phase 2 |
Preceding treatment
- Induction OPPA x 2
Chemotherapy
- Cyclophosphamide (Cytoxan) 500 mg/m2 IV once per day on days 1 & 8
- Vincristine (Oncovin) 1.5 mg/m2 IV once per day on days 1 & 8
- Procarbazine (Matulane) 100 mg/m2 PO once per day on days 1 to 15
Glucocorticoid therapy
- Prednisone (Sterapred) 40 mg/m2 PO once per day on days 1 to 15
28-day cycle for 4 cycles
References
- GPOH-HD-2002: Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. link to original article contains dosing details in manuscript PubMed NCT00416832
COPDAC
COPDAC: Cyclophosphamide, Oncovin (Vincristine), Prednisone, DACarbazine
Regimen variant #1, 2 cycles
Study | Dates of enrollment | Evidence |
---|---|---|
Mauz-Körholz et al. 2010 (GPOH-HD-2002) | 2002-2005 | Phase 2 |
Preceding treatment
- Induction OEPA x 2
Chemotherapy
- Cyclophosphamide (Cytoxan) 500 mg/m2 IV once per day on days 1 & 8
- Vincristine (Oncovin) 1.5 mg/m2 IV once per day on days 1 & 8
- Dacarbazine (DTIC) 250 mg/m2 IV once per day on days 1 to 4
Glucocorticoid therapy
- Prednisone (Sterapred) 40 mg/m2 PO once per day on days 1 to 15
28-day cycle for 2 cycles
Regimen variant #2, 4 cycles
Study | Dates of enrollment | Evidence |
---|---|---|
Mauz-Körholz et al. 2010 (GPOH-HD-2002) | 2002-2005 | Phase 2 |
Preceding treatment
- Induction OEPA x 2
Chemotherapy
- Cyclophosphamide (Cytoxan) 500 mg/m2 IV once per day on days 1 & 8
- Vincristine (Oncovin) 1.5 mg/m2 IV once per day on days 1 & 8
- Dacarbazine (DTIC) 250 mg/m2 IV once per day on days 1 to 4
Glucocorticoid therapy
- Prednisone (Sterapred) 40 mg/m2 PO once per day on days 1 to 15
28-day cycle for 4 cycles
References
- GPOH-HD-2002: Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. link to original article contains dosing details in manuscript PubMed NCT00416832